Surveillance of Iclaprim Activity: In Vitro Susceptibility of Gram-positive Pathogens Collected from 2012 to 2014 From the United States, Asia Pacific, Latin American and Europe

Iclaprim is a novel diaminopyrimidine, which inhibits bacterial dihydrofolate reductase, and it is highly active against Gram-positive pathogens including emerging drug-resistant pathogens. In vitro activity of iclaprim and comparators against 2814 Gram-positive clinical isolates from the United States, Asia Pacific, Latin American and Europe collected between 2012 and 2014 were tested. Susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.

Source: Diagnostic Microbiology and Infectious Disease - December 7, 2017 Category: Microbiology Authors: David B Huang, Thomas M File, Matthew Dryden, G. Ralph Corey, Antoni Torres, Mark H Wilcox Source Type: research